Nobel Biocare further extends its product portfolio at EAO news At its press conference on Thurs- day morning, Switzerland-based com- pany Nobel Biocare announced the next step in its digital workflow with a new option for same-day guided sur- gery made possible by DTX Studio Im- plant and the X-Guide dental naviga- tion system. In addition, the company is introducing creos mucogain, a re- sorbable collagen matrix for soft- tissue regeneration, as well as the NobelPro Line, in order to highlight the possibilities of Nobel Biocare’s comprehensive range of edentulous treatment solutions. With X-Guide, being demonstrated at the fully equipped Nobel Biocare lounge by Dr Pascal Kunz, clinicians have a new treatment option for same- day surgery. DTX Studio Implant em- powers this innovative system for dy- namic 3-D navigation. With the soft- ware officially being launched for Eu- ropean markets at the EAO congress, treatment plans from DTX Studio Im- plant (formerly NobelClinician) can now be instantly delivered to the pa- tient, providing a workflow for diag- nostics, implant planning and dynam- ically navigated implant surgeries, even during emergency interventions where computer-assisted surgeries until now could not be fully applied. Using DTX Studio Implant and X-Guide, clinicians can achieve high precision, shorter time-to-teeth treat- ments, including screw-retained pro- visionalisation with full 3-D control of their implant site preparation and dy- namically monitored implant inser- tion. The procedure only takes min- utes from the CBCT scanning to the start of the surgery. Similar to a GPS in a car, X-Guide provides stable, lag- free, real-time 3-D intraoral guidance of the drill and implant position in re- lation to patient anatomy. X-Guide is manufactured by X-Nav Technologies, a North America-based innovator in dental 3-D navigation who has exclu- sively partnered with Nobel Biocare. Extending Nobel Biocare’s range of solutions for guided bone and tissue © Nobel Biocare Hans Geiselhöringer, President of Nobel Biocare, welcomed media and industry partners to the company’s press conference on 11 October 2018. regeneration, the new creos mucogain resorbable collagen matrix is intended to be used as an alternative for autolo- gous soft-tissue grafts in various soft-tissue indications, such as soft-tis- sue volume augmentation and root coverage in submerged healing. Com- posed of highly purified porcine colla- gen and elastin fibres, it has an open interconnecting porous structure de- signed to promote soft-tissue regenera- tion through the migration of cells and blood vessels into the matrix.1, 2 The matrix offers high stress re- sistance and suture retention2 that is sufficient for the tunnelling tech- nique.3 Owing to a memory effect, it retains its initial volume when hy- drated.2 creos mucogain is available in different sizes (15 × 20 mm and 25 × 30 mm) and thicknesses (3 mm and 5 mm). According to Nobel Biocare, it offers excellent handling, as it can be used directly out of the packaging and trimmed to precisely fit the surgical site.3 Highlighting its range of eden- tulous treatment solutions, Nobel Biocare is further announcing the NobelPro Line to showcase the bene- fits of immediate function, along with the latest advancements in mini- mally invasive care. With an assort- ment of clinically successful and proven treatment options, including NobelSpeedy and NobelZygoma, cli- nicians can take the All-on-4 treat- ment concept to new heights and treat even the most challenging max- © Monique Mehler, DTI © Monique Mehler, DTI Tinne Van Delm (left), Head Global Product Management Software at Nobel Biocare, and Dr Kunz showcased the multiple software solutions that the company offers in its extensive portfolio. Together with Dr Kunz (left), X-Nav Co-Founder, President and CEO Ed Marandola demonstrated the X-Guide. illary cases with moderate up to se- vere resorption. At the press conference, Presi- dent of Nobel Biocare Hans Geisel- höringer said, “Nobel Biocare has once again shown that it is a leading force in bringing cutting-edge tech- nology and solutions to clinicians worldwide. With the addition of dy- namic navigation to its digital work- flow, Nobel Biocare looks forward to helping more clinicians leverage the latest in implant treatment technol- ogy. Together with forward-looking regenerative solutions like creos mu- cogain, as well as the NobelPro Line, they now have better treatment op- tions available to lead more patients to immediate function and excellent aesthetics.” Clinical insights on X-Guide, creos mucogain and the NobelPro Line will be given during clinical lec- tures and hands-on courses pre- sented by Nobel Biocare in Vienna. More information is available at Booth D-02 and online at http://www. nobelbiocare.com/eao. References 1 Boekema BK, Vlig M, Olde Damink L, Middelkoop E, Eummelen L, Bühren AV, Ulrich MM. Effect of pore size and cross-linking of a novel colla- gen-elastin dermal substitute on wound healing. J Mater Sci Mater Med. 2014 Feb;25(2):423–33. 2 Olde Damink L, Heschel I, Leemhuis H, Tortorici M, Wessing B. Soft tissue volume augmentation in the oral cav- ity with a collagen-based 3D matrix with orientated open pore structure. CDBME. 2018 Sep;4(1):237–41. 3 Wessing B, Vasilic N. Soft tissue aug- mentation with a new regenerative collagen 3-D matrix with oriented open pores as a potential alternative to autologous connective tissue Implants Res. grafts. Clin Oral 2014;25(10 Suppl):342. Available from: www.dentalcongressposters. com/eao2014/wessing.pdf Dreams in implant dentistry turn into reality at EAO 2018 EAO President Dr Alberto Sicilia Felechosa took the stage at the opening ceremony of the 27th An- nual Scientific Meeting of the EAO and welcomed the attendees, many of whom have travelled from far to Vienna to attend the congress. “We worked very hard to make this happen and are more than happy to see you here,” he said in officially announcing the start of the con- gress. Following this, the induction of Prof. Christoph Hämmerle as an EAO honorary member took place. The honorary membership is the highest award that the EAO can bestow on individuals who have contributed greatly both to the science of implant dentistry and to the association. Only five individuals have received this recognition. Felechosa said that he was “delighted to present this award” to Hämmerle in acknowledgement of his outstanding efforts. “The EAO is close to my heart. I have great mem- ories with great people,” Hämmerle © Monique Mehler, DTI Dr Felechosa officially opened the 27th EAO congress. said as he accepted his award to a standing ovation. Afterwards, the moderator of the main scientific programme, Steward Freeman, was introduced to the audi- ence. He then gave an overview of the programme and highlights for the next three days. A “time machine video”, as Free- man called it, introduced the EAO congress scientific committee, who took the viewers through the cultur- ally rich and eventful history of Vienna. Chairman Prof. Ronald Jung and Co-Chairmen Prof. Georg Mailath- Pokorny, and Dr Michael Payer then entered the stage for their addresses. In conveying their exper ience of compiling the programme, Jung said, “The three of us started with one dream: making the most suc- cessful and most amazing congress happen.” Mailath-Pokorny and Payer ended the ceremony with short speeches, before continuing with the opening session for the live treat- ment sessions. These will stretch over the course of the next three days and include live surgeries and follow-up care as a major highlight of the EAO 2018 scientific pro- gramme. 2 27 th EAO Annual Scientific Meeting